Comparison of galactomannan enzyme immunoassay performance levels when testing serum and plasma samples

Clinical and Vaccine Immunology

Volumn 20, Issue 4, 2013, Pages 636-638

  White, P Lewis ^a   Jones, Tim ^a   Whittle, Katie ^a   Watkins, Joanne ^a   Barnes, Rosemary A ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; VALIDATION STUDY;

ANTIGENS, FUNGAL; ASPERGILLOSIS; CLINICAL LABORATORY TECHNIQUES; HUMANS; IMMUNOENZYME TECHNIQUES; MANNANS; PLASMA; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 84876498428     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00730-12     Document Type: Article

References (7)

1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46: 1813-1821.
2. Bio-Rad. 2011. Platelia Aspergillus Ag: Instruction manual. Bio-Rad, Marnes-la-Coquette, France.
3. Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J. 2009. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J. Clin. Pathol. 62:64-69.
4. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CM. 2008. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst. Rev. 2008:CD007394. doi:10.1002 /14651858.CD007394.
5. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin. Infect. Dis. 34:7-14.
6. Nucci M, Nouér SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. 2010. Probable invasive aspergillosis without prespecified radiologic findings: Proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin. Infect. Dis. 51:1273-1280.
7. Maertens J, Theunissen K, Lagrou K. 2010. Galactomannan testing, p 105-124. In Pasqualott AC (ed), Aspergillosis: From diagnosis to prevention. Springer Press, New York, NY.